CentoICU – For the Earliest and Fastest Diagnosis
For the earliest and fastest diagnosis of critically ill newborns and children under 24 months in intensive care units (ICU).
CentoICU is designed to diagnose genetic conditions that manifest in newborns or in early childhood. Many of these conditions have overlapping phenotypes and diagnosis may have immediate implications for the treatment.
Newborns and children under 24 months presenting with life-threatening conditions need a fast and precise diagnosis to ensure rapid and efficient further diagnostic and therapeutic initiation.
Up to one-third of all babies and children admitted to the ICU have a genetic disease. For many of them early identification can make the difference for their immediate and later health.
CentoICU is a comprehensive NGS panel that includes more than 850 genes, explicitly selected for the genetic testing of critically ill newborns and children under 24 months. It is designed to address multiple genetic conditions that may present in the newborn or first childhood period, many with overlapping phenotypes and immediate implications for treatment initiation. It allows clinicians to utilize just one single test to provide an accurate diagnosis of newborn-related diseases.
Why Choose CentoICU?
Minimal sample requirement (just 0.5 ml blood, 1 µg DNA or 1 filter card)
Screening of more than 850 genes associated with over 100 conditions
Short turnaround times – ten business days is possible
World-class medical reports interpreted by expert human geneticists
Turn around time
Short TATs: 10 business days (CentoICU FAST) or 15 business days (CentoICU)
Comprehensive coverage of coding regions known to cause diseases in newborns
Screens newborns for all ACMG-recommended conditions and those nominated for inclusion.
CentoICU allows clinicians to utilize one test to provide an accurate assessment for newborn-related genes and associated genetic diseases using dried blood spots, and it provides fast delivery of the results in less than 15 business days.
CentoICU is indicated for newborns and children under 24 months admitted to the ICU and presenting with unclear symptomatology which can be part of a genetic condition, i.e.
- Bleeding dyathesis
- Blood abnormalities (anemia)
- Bone fragility
- Failure to thrive
- Heart abnormality/arrhythmia
- Ichthyosis/epidermolysis bullosa
- Metabolic abnormalities*
- Abnormal newborn screening results**
- Respiratory failure
- Skeletal abnormalities/craniosynostosis
- Skin fragility
- Unclear seizures
*) Abnormal acylcarnitine profile, amino acidemia/urea, hyperbilirubinemia, hyper-/hypoinsulinism, persistent hypoglycemia, organic acidemia/urea
**) CentoICU includes genes to cover all ACMG core panel phenotypes for newborn screening except hearing loss
|Alagille syndrome||NOTCH2, JAG1|
|Biotin-thiamine-responsive basal ganglia disease||SLC19A3|
|Dystonia DOPA responsive||GCH1|
|Factor VII deficiency||F7|
|Glucose transporter 1 deficiency||SLC2A1|
|Glutaric acidemia Type 1||GCDH|
|Hereditary Fructose intolerance||ALDOB|
|Holocarboxylase synthetase deficiency||HLCS|
|Maple syrup urine disease (MSUD)||BCKDHA, BCKDHB, DBT|
|Non ketotic hyperglicinemia||GLDC|
|Primary coenzyme Q10 deficiency||COQ8A|
|Pyridoxamine 5 phosphate oxidase deficiency||PNPO|
|Pyruvate carboxylase deficiency||PC|
|Tuberous sclerosis complex||TSC1|
|Tuberous sclerosis complex||TSC2|
|Tyrosinemia Type I||FAH|
*List does not include all disorders covered by our panel
**This panel does not detect intronic inversions for F8
CentoICU is designed for analysis more than 850 genes associated with over 100 conditions. The list of included genes was developed by our expert medical team based on several selection criteria, i.e.:
- Early onset
- Severe disease
- ICU related symptomatology
- Diseases/syndromes of differential diagnostic value
A Multiomic Approach to Diagnosing Patients and Accelerating Treatments
An approach which integrates genetic and biochemical testing as first-line diagnostic tool for patients with inherited metabolic disorders.
Broader Applicability of Rare Disease Biomarker
Biomarkers have the potential to serve numerous purposes (diagnosis, prognosis, monitoring, etc.) when well-characterized in large cohorts of patients and controls. Building on its rich source of […]
NEW CentoXome®: convirtiendo nuestra experiencia en su ventaja
Los oradores del webinar, la Dra. Pilar Guatibonza, Clinical Genetic Liaison CENTOGENE, y el Dr. Carlos Manrique, Gerente Regional de Ventas en México CENTOGENE, discuten el poder del NEW CentoXome […]
Cómo los biomarcadores transforman los diagnósticos genéticos
A lo largo del seminario web, Pilar Guatibonza, MD, y Carlos Manrique, MD, brindan una descripción general de cómo los biomarcadores multiómicos desempeñan un papel esencial en el diagnóstico […]
How Biomarkers Transform Genetic Diagnostics
Throughout the webinar, Dr. Tobias Böttcher provided an overview of how multiomic biomarkers play an essential role in early diagnosis, prediction, and therapeutic monitoring of Niemann-Pick Disease […]